


Dicyclomine

Cat. No.:	HY-B1339A
CAS No.:	77-19-0
Molecular Formula:	C ₁₉ H ₃₅ NO ₂
Molecular Weight:	309.49
Target:	mAChR
Pathway:	GPCR/G Protein; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Dicyclomine (Dicycloverine) is a potent and orally active muscarinic cholinergic receptors antagonist. Dicyclomine (Dicycloverine) shows high affinity for muscarinic M1 receptor subtype ($K_i=5.1$ nM) and M2 receptor subtype ($K_i=54.6$ nM) in brush-border membrane and basal plasma membranes, respectively ^[1] . Dicyclomine is an antispasmodic agent and relieves smooth muscle spasm of the gastrointestinal tract in vivo ^[2] .								
In Vivo	<p>Dicyclomine (Dicycloverine) (intraperitoneal injection; 8 mg/kg; daily) exacerbates the cognitive impairments in all the measurements. In addition, the memory impairments are worse in dicyclomine-treated 3xTg-AD mice compared to dicyclomine-treated NonTg mice^[2].</p> <p>Dicyclomine (Dicycloverine) (intraperitoneal injection; 2.0, 4.0, and 8.0 mg/kg; 7 days) produces a highly significant effect on performance in the paired-associates learning (PAL) task in mice. And systemic treatment at lower doses show behavioral impairments in mice in spatial tasks^[3].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>C57Bl/6 mice^[1]</td> </tr> <tr> <td>Dosage:</td> <td>2.0, 4.0, and 8.0 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; daily; 7 days</td> </tr> <tr> <td>Result:</td> <td>Produced impairments due to actions of the agent outside of the hippocampus.</td> </tr> </table>	Animal Model:	C57Bl/6 mice ^[1]	Dosage:	2.0, 4.0, and 8.0 mg/kg	Administration:	Intraperitoneal injection; daily; 7 days	Result:	Produced impairments due to actions of the agent outside of the hippocampus.
Animal Model:	C57Bl/6 mice ^[1]								
Dosage:	2.0, 4.0, and 8.0 mg/kg								
Administration:	Intraperitoneal injection; daily; 7 days								
Result:	Produced impairments due to actions of the agent outside of the hippocampus.								

REFERENCES

[1]. Antonella Caccamo, et al. M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. 2006 Mar 2;49(5):671-82.doi: 10.1016/j.neuron.2006.01.020.

[2]. Antonella Caccamo, et al. M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. 2006 Mar 2;49(5):671-82.doi: 10.1016/j.neuron.2006.01.020.

[3]. Susan J Bartko, et al. A Computer-Automated Touchscreen Paired-Associates Learning (PAL) Task for Mice: Impairments Following Administration of Scopolamine or Dicyclomine and Improvements Following Donepezil. Psychopharmacology (Berl). 2011 Mar;214(2):537-48.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA